The Unseen Force

The Unseen Force By Aaron BlockerSenior Advisor: Advocacy / Market Access Empowering Market Access for Rare Disease Therapies Through Patient Advocacy Developing a life-saving therapy for a rare disease is a triumph of scientific innovation and perseverance. However, translating this groundbreaking research into real-world patient access is a complex undertaking, particularly in the multifaceted global […]

The Rare Disease Market in APAC: Challenges and Opportunities

The Rare Disease Market in APAC

The Rare Disease Market in APAC By Chad JiRare Disease Expert – South Korea The rare disease sector can broadly be divided into oncology and ultra-rare disease areas. Today, we will focus on the ultra-rare disease segment (referred to as “rare diseases” hereafter). Most of the insights and content discussed are based on my personal […]

Hurdles to Harmonization

US Biotech in Europe

Don’t Sleep On The EU! Hurdles to Harmonization A Strategic Guide for Biotech and Pharma Facing FDA Setbacks in Rare Disease Therapy Development Experiencing a setback with the FDA in your rare disease therapy development can feel like a significant hurdle. However, it’s important to remember that the journey doesn’t end there. The European Medicines […]

The Global Ambition

Dont Sleep on the EU Global Ambition

Don’t Sleep On The EU! The Global Ambition The rare disease landscape is evolving rapidly, with groundbreaking scientific advancements and novel therapeutic approaches emerging at an unprecedented pace. For biotech and pharmaceutical companies venturing into this dynamic space, navigating the complex regulatory pathways for approval in both the US and Europe is paramount. A well-orchestrated […]

EU As A Launch Pad

EU As a Launch Pad

EU As A Launch Pad Think Global, Start European: A Strategic Launchpad for Rare Disease Therapies The global rare disease landscape is evolving rapidly, with increasing investment and a growing pipeline of innovative therapies. Yet, navigating the complex regulatory and market access pathways remains a significant challenge for biotech and pharmaceutical companies. In this context, […]